Novartis's Blockbuster Gilenya Cleared For Children And Adolescents In Europe
Novartis's blockbuster MS drug is now approved for children and adolescent use in the EU as well as the US, as the big pharma continues to build its MS franchise in advance of the start of generic competition to Gilenya, expected sometime after mid-2019.
You may also be interested in...
A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.
As Novartis prepares its imminent US filing for its Gilenya follow-up siponimod some experts are underwhelmed by its pivotal EXPAND study.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.